XENT Intersect ENT Inc.

24.81
+0.02  (+0%)
Previous Close 24.79
Open 24.24
Price To Book 7.05
Market Cap 781,884,694
Shares 31,514,901
Volume 247,667
Short Ratio
Av. Daily Volume 455,586
Stock charts supplied by TradingView

NewsSee all news

  1. Intersect ENT Reports Preliminary Full Year 2019 Revenue

    Intersect ENT, Inc. (NASDAQ:XENT), a company transforming care for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the full year ended December 31, 2019. Full Year 2019

  2. Cardiva Medical Appoints Jeri Hilleman to the Company's Board of Directors

    Company to Present at the 38th Annual J.P. Morgan Healthcare Conference Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl ("Jeri")

  3. Intersect ENT to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Intersect ENT, Inc. (NASDAQ:XENT), today announced that management will participate in the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at the Westin St. Francis Hotel in San Francisco,

  4. SI-BONE Names Jeryl ("Jeri") Hilleman to Board of Directors

    SANTA CLARA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today

  5. Intersect ENT Announces Appointment of New Chief Financial Officer

    Richard A. Meier to serve as Executive Vice President and Chief Financial Officer Intersect ENT®, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved March 2016
Propel
Frontal Sinus Disease
Approval announced December 11, 2017.
SINUVA Sinus Implant
Recurrent sinus obstruction
Phase 3 trial met primary endpoints - February 25, 2019.
SINUVA - ENCORE
Nasal polyps
Data released October 7, 2019 did not meet primary endpoint.
ASCEND
Sinus Balloon

Latest News

  1. Intersect ENT Reports Preliminary Full Year 2019 Revenue

    Intersect ENT, Inc. (NASDAQ:XENT), a company transforming care for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the full year ended December 31, 2019. Full Year 2019

  2. Cardiva Medical Appoints Jeri Hilleman to the Company's Board of Directors

    Company to Present at the 38th Annual J.P. Morgan Healthcare Conference Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl ("Jeri")

  3. Intersect ENT to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Intersect ENT, Inc. (NASDAQ:XENT), today announced that management will participate in the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at the Westin St. Francis Hotel in San Francisco,

  4. SI-BONE Names Jeryl ("Jeri") Hilleman to Board of Directors

    SANTA CLARA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today

  5. Intersect ENT Announces Appointment of New Chief Financial Officer

    Richard A. Meier to serve as Executive Vice President and Chief Financial Officer Intersect ENT®, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today

  6. Intersect ENT to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Intersect ENT, Inc.

  7. Intersect ENT Reports Third Quarter 2019 Results

    Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2019. Total

  8. Intersect ENT to Report Third Quarter 2019 Financial Results

    Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release third quarter financial results on November 1, 2019.

  9. Intersect ENT Announces Results From the ASCEND Study of Company's Investigational Drug-Coated Balloon for Sinus Dilation

    Intersect ENT®, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced results from a study of the company's ASCEND investigational drug-coated

  10. Shareholder Alert: Robbins Arroyo LLP Reminds Investors Intersect ENT, Inc. (XENT) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Intersect ENT, Inc. (NASDAQ:XENT) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between